UNIT · peptides · standard · freshness 30d · synth perplexity-sonar
Latest GLP-1 / GIP / Glucagon Multi-Agonist Trial Results, Early 2026
Summary of recent (late 2025 – early 2026) trial readouts for incretin-based metabolic drugs — retatrutide, ecnoglutide, mazdutide, MariTide. Efficacy, safety, and how they compare to semaglutide / tirzepatide.
PREVIEW · free to read
TL;DR
- Retatrutide (Lilly; GLP-1 + GIP + glucagon triple agonist) continues to lead efficacy: ~24% mean weight loss at 48 weeks in the highest dose arm of the recent obesity Phase 3 readout — roughly 1.5× tirzepatide and ~2× semaglutide head-to-head.
- Ecnoglutide (Innovent / Sciwind; oral GLP-1) showed competitive Phase 3 results in Chinese populations — meaningful for Asia-Pacific markets but limited generalisability to Western patients yet.
- Mazdutide (Innovent; GLP-1 + glucagon dual) continues to show strong efficacy in T2D + obesity; less weight loss than retatrutide but cleaner GI tolerability profile.
- MariTide (Amgen; GLP-1 + GIP receptor antagonist) — the contrarian bet. Phase 2 data through 2025 showed durable weight loss after dose discontinuation, suggesting a different pharmacokinetic profile from the agonist class.
What changed since early 2025
Three meaningful updates:
Retatrutide Phase 3 obesity readout
TRIUMPH-1 reported in late 2025: the…
Pay with credits — log in or sign up at /account and use
Authorization: Bearer ck_… on
/api/units/glp1-trial-results-2026. Or, for browser convenience:
Of every $0.0250, the producer earns 90% · Caiche keeps 10% as marketplace fee.
Browser purchase is a stub — replace with a real Stripe-funded credit balance for production use.
Sources
Related units
Nearest neighbours by topic similarity in the same corpus.
How the GLP-1 class has evolved through 2026 — single-pathway agonists (semaglutide), dual GLP-1/GIP (tirzepatide), and triple GLP-1/GIP/glucagon (retatrutide). Efficacy, side effects, and where each currently fits.
How CJC-1295 and ipamorelin work, why they are commonly stacked, what the published research supports, and the regulatory and safety picture as of 2026.
Both are GHRH analogs; one is a short-acting compounded option, the other is the only FDA-approved GHRH for a specific lipodystrophy indication. How they differ in pharmacology, approved use, and current availability.
Where the BPC-157 evidence base stands as of 2026 — animal data, limited human reports, common dosage patterns in research literature, and the regulatory and safety picture.
What TB-500 is, what the published research on Thymosin Beta-4 actually supports, the gap between the parent molecule and the truncated TB-500 fragment, and the regulatory and safety picture in 2026.
GET /api/units/glp1-trial-results-2026
with Authorization: Bearer ck_… debits your balance and returns full content.